Can My GP Prescribe Semaglutide for Weight Loss?

Possibly—but access depends on why you need semaglutide, where you live, and whether you are seeking NHS or private treatment. In the UK, a GP may discuss weight-management medicines, assess your health, and help you navigate referral pathways. However, NHS treatment with semaglutide for weight loss is generally linked to specialist services and local prescribing arrangements. It is not usually a matter of asking for a prescription at a routine appointment.

It also helps to distinguish between the brands. Wegovy is the semaglutide brand licensed for weight management in the UK. Ozempic contains the same active ingredient but is licensed for type 2 diabetes, not weight loss. A GP should prescribe a medicine for an appropriate clinical indication, rather than use Ozempic as a substitute for Wegovy.

This guide explains how the medicine works, what trials have found, what NICE guidance says, and what to expect from monitoring and follow-up. Eligibility and local services can change, so confirm current arrangements with your GP or NHS weight-management service.

What Is Semaglutide and How Does It Work?

Semaglutide belongs to a group of medicines called GLP-1 receptor agonists. GLP-1 is a gut hormone involved in appetite and blood-sugar regulation. Semaglutide acts on GLP-1 receptors, helping people feel fuller and less hungry, and often reducing how much they eat. It also slows stomach emptying to some extent and helps the body release insulin when blood sugar is high.

For weight management, semaglutide is supplied as a once-weekly injection. The dose is increased gradually over several weeks to help the body adjust and reduce digestive side effects. It is intended to be used alongside support such as changes to eating habits and physical activity—not as a stand-alone quick fix.

People respond differently. Some experience substantial weight loss; others lose less or find side effects make treatment difficult. Weight regain can occur after stopping, so it is important to discuss a longer-term plan with the prescribing team before starting.

What Does the Evidence Say?

Semaglutide has been studied in randomized controlled trials (RCTs), including the STEP program. These trials tested the medicine alongside lifestyle support and compared it with placebo. Results show that, on average, participants taking semaglutide for weight management lost more weight than those receiving placebo. The results do not predict exactly what will happen for any one person.

• STEP 1: In adults with overweight or obesity without diabetes, average weight loss was about 14.9% after 68 weeks with semaglutide 2.4 mg, compared with about 2.4% with placebo. Both groups received lifestyle support.
• STEP 2: In adults with overweight or obesity and type 2 diabetes, average weight loss was about 9.6% with semaglutide 2.4 mg, compared with about 3.4% with placebo after 68 weeks.
• STEP 4: Participants who continued semaglutide after an initial treatment period generally maintained or increased weight loss, while those switched to placebo regained weight on average.

These results support semaglutide as an effective option for some people, but they come from trials with defined eligibility, regular follow-up, and lifestyle advice. They do not mean that everyone will achieve the average result, or that the medicine is suitable without medical assessment.

Can a GP Prescribe It on the NHS?

GP prescribing depends on the treatment indication and the local pathway. NHS access to Wegovy for weight management is generally through an approved specialist weight-management service, rather than routine prescribing in primary care. In some areas, a GP may refer you to the service; in others, access may be organized differently. If treatment is recommended, prescribing may remain with the specialist team or transfer to a GP under an agreed shared-care arrangement, where that arrangement exists.

That means a GP can be an important starting point without necessarily being the person who initiates or manages treatment. Your GP can review your health, discuss whether referral is appropriate, check for relevant conditions or medicines, and explain what local options are available. If you have type 2 diabetes, semaglutide may also be considered as part of diabetes treatment, but the decision and brand depend on the clinical indication and local diabetes pathway.

Private treatment may follow different arrangements, but it still requires a proper clinical assessment and follow-up. A private provider should check your medical history, explain risks and alternatives, and arrange monitoring. A prescription obtained without appropriate assessment is not a safe shortcut.

NICE Guidance and Eligibility Criteria

NICE guidance for semaglutide weight management describes use in adults who meet specified criteria and receive support from a specialist weight-management service. In broad terms, the criteria include:

• A body mass index (BMI) of 35 or higher, with at least one weight-related health condition; or
• A BMI from 30 to 34.9, with at least one weight-related health condition and eligibility for referral to specialist weight-management services.

Lower BMI thresholds may apply for people from certain ethnic backgrounds, because weight-related health risks can occur at lower BMI levels. NICE also sets out a time-limited approach: treatment is generally offered for up to two years within the specified service arrangements, alongside a reduced-calorie diet and increased physical activity. The specialist team should consider whether to stop treatment if a person has lost less than 5% of their initial weight after six months on the highest tolerated dose.

These are national recommendations, not a guarantee of immediate treatment. Local service capacity, commissioning arrangements, clinical suitability, and the online semaglutide risks exact referral pathway can affect access. Your GP or local service can confirm the current criteria where you live.

Question What to expect Who assesses eligibility? Usually a specialist weight-management service, with GP involvement in referral or ongoing care depending on local arrangements. What supports treatment? Dietary and activity support, gradual dose increases, and regular review of benefits and side effects. How long is NHS treatment? NICE guidance describes a maximum of two years in the specified service pathway; local arrangements should be checked. What if weight loss is limited? The specialist team may consider stopping if weight loss is less than 5% after six months on the highest tolerated dose.

Side Effects and Monitoring Requirements

The most common side effects affect the digestive system. They may be more noticeable when treatment starts or the dose increases, and some improve over time. Common effects include nausea, vomiting, diarrhea, constipation, abdominal discomfort, and reduced appetite. Smaller meals and gradual dose escalation may help, but persistent or severe symptoms should be discussed with the prescriber.

Less common but important risks include gallbladder problems, such as gallstones, and inflammation of the pancreas (pancreatitis). Repeated vomiting or diarrhea can cause dehydration and may affect kidney function. People with diabetes who also use insulin or certain medicines such as sulfonylureas may have a greater risk of low blood sugar, so their diabetes treatment may need review.

Semaglutide should not be used during pregnancy. Anyone planning a pregnancy should discuss timing with their prescriber; product guidance advises stopping semaglutide at least two months before a planned pregnancy. Tell the clinician about breastfeeding, existing medical conditions, and all medicines or supplements you take before treatment begins.

What monitoring may involve

Monitoring requirements are not identical for everyone, but a responsible service will review your progress and check that treatment remains suitable. This may include:

• Recording weight, BMI, and relevant health measures at baseline and follow-up.
• Reviewing dose increases, appetite changes, weight response, and side effects.
• Checking medical history and medicines, including diabetes treatments and medicines affected by slower stomach emptying.
• Assessing hydration and considering kidney function tests if significant vomiting, diarrhea, or other clinical concerns occur.
• Discussing contraception, pregnancy plans, and symptoms that need urgent medical attention.

Seek urgent medical advice for severe, persistent abdominal pain, especially if it spreads to your back, or for signs of a serious allergic reaction. Contact your clinical team if you cannot keep fluids down, have ongoing vomiting or diarrhea, or develop symptoms that worry you.

Be Cautious About Online Marketplaces and Social Media Channels

Demand for semaglutide has led to promotion through online marketplaces and social media channels. These can make the medicine look easy to obtain, but they are not a substitute for a legitimate prescription and clinical follow-up. Products sold through unverified sources may be counterfeit, improperly stored, the wrong dose, or not semaglutide at all.

Do not buy injectable medicines from informal sellers or use someone else’s pen. If considering private care, check that the provider is appropriately regulated, that a qualified prescriber assesses you, and that the medicine is supplied through a legitimate pharmacy. Ask who will monitor you and what happens if you experience side effects or need to stop.

How to Discuss GP Prescribing and Referral Pathways

If you want to explore treatment, you can make the appointment more useful by preparing a few details. Be ready to discuss your weight history, previous approaches, health conditions, current medicines, and any symptoms or concerns. You can ask:

1. Do I meet the current criteria for referral to a specialist weight-management service?
2. What are the local referral pathways, and who would prescribe if treatment is recommended?
3. What support is available alongside medication, including nutrition and activity guidance?
4. What monitoring will I need, and whom should I contact if side effects occur?
5. What alternatives are appropriate if semaglutide is unsuitable or unavailable?

It may also help to agree on goals beyond the number on the scale, such as improved blood pressure, mobility, fitness, post marketing safety GLP-1 or blood-sugar control. A supportive plan should be individualized and should not rely on blame or unrealistic promises.

The Bottom Line

A GP can help assess whether semaglutide may be appropriate and explain referral pathways, but NHS Wegovy for weight loss is generally managed through specialist services and local arrangements. NICE guidance sets out eligibility and review criteria, while RCTs—including the STEP trials—show meaningful average weight loss when treatment is combined with lifestyle support. Because side effects, medical history, and ongoing monitoring matter, use semaglutide only through a legitimate prescribing service. Ask your GP what is currently available in your area and what a safe, sustainable weight-management plan could look like for you.